Skip to main content


Figure 5 | BMC Cancer

Figure 5

From: Targeting of CD34+CD38-cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

Figure 5

Pgp function is inhibited by tipifarnib. (a) Rhodamine 123 modulation ratio 75 minutes after treatment is shown in Pgp positive (KG-1a) and Pgp negative control (U937) cells treated with 2.5 μg/ml cyclosporin A, 5 μM vinblastine, 20 μM verapamil or 5 μM tipifarnib, mean +/− standard deviation of three separate assays (b) Rhodamine modulation by tipifarnib compared to cyclosporin in three different primary AML samples. (c) Percentage loss of viable cells is shown following 48 hour culture of nine Pgp positive and twenty three Pgp negative primary samples. Median values are shown by solid bars

Back to article page